Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 15;187(4):861-881.e32.
doi: 10.1016/j.cell.2024.01.008. Epub 2024 Jan 31.

SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion

Giuseppe Leuzzi  1 , Alessandro Vasciaveo  2 , Angelo Taglialatela  1 , Xiao Chen  1 , Tessa M Firestone  3 , Allison R Hickman  3 , Wendy Mao  4 , Tanay Thakar  1 , Alina Vaitsiankova  1 , Jen-Wei Huang  1 , Raquel Cuella-Martin  1 , Samuel B Hayward  1 , Jordan S Kesner  2 , Ali Ghasemzadeh  4 , Tarun S Nambiar  1 , Patricia Ho  5 , Alexander Rialdi  6 , Maxime Hebrard  7 , Yinglu Li  1 , Jinmei Gao  8 , Saarang Gopinath  3 , Oluwatobi A Adeleke  3 , Bryan J Venters  3 , Charles G Drake  9 , Richard Baer  10 , Benjamin Izar  11 , Ernesto Guccione  6 , Michael-Christopher Keogh  3 , Raphael Guerois  8 , Lu Sun  3 , Chao Lu  1 , Andrea Califano  12 , Alberto Ciccia  13
Affiliations

SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion

Giuseppe Leuzzi et al. Cell. .

Abstract

Genomic instability can trigger cancer-intrinsic innate immune responses that promote tumor rejection. However, cancer cells often evade these responses by overexpressing immune checkpoint regulators, such as PD-L1. Here, we identify the SNF2-family DNA translocase SMARCAL1 as a factor that favors tumor immune evasion by a dual mechanism involving both the suppression of innate immune signaling and the induction of PD-L1-mediated immune checkpoint responses. Mechanistically, SMARCAL1 limits endogenous DNA damage, thereby suppressing cGAS-STING-dependent signaling during cancer cell growth. Simultaneously, it cooperates with the AP-1 family member JUN to maintain chromatin accessibility at a PD-L1 transcriptional regulatory element, thereby promoting PD-L1 expression in cancer cells. SMARCAL1 loss hinders the ability of tumor cells to induce PD-L1 in response to genomic instability, enhances anti-tumor immune responses and sensitizes tumors to immune checkpoint blockade in a mouse melanoma model. Collectively, these studies uncover SMARCAL1 as a promising target for cancer immunotherapy.

Keywords: AP-1; CRISPR-Cas9 screens; DNA damage response; JUN; PD-L1 regulation; SMARCAL1; cGAS-STING pathway; cancer immunotherapy; cancer-intrinsic innate immunity.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests EpiCypher is a commercial developer and supplier of reagents and platforms used in this study. All authors affiliated with EpiCypher own shares in (with M.-C.K. also a board member of) EpiCypher Inc. B.I. is a consultant for or received honoraria from Volastra Therapeutics, Johnson & Johnson/Janssen, Novartis, Eisai, AstraZeneca, and Merck and has received research funding to Columbia University from Agenus, Alkermes, Arcus Biosciences, Checkmate Pharmaceuticals, Compugen, Immunocore, and Synthekine. A. Califano is founder, equity holder, and consultant of DarwinHealth Inc., a company that has licensed some of the algorithms used in this manuscript from Columbia University. Columbia University is also an equity holder in DarwinHealth Inc.

Similar articles

See all similar articles

References

    1. Del Poggetto E, Ho IL, Balestrieri C, Yen EY, Zhang S, Citron F, Shah R, Corti D, Diaferia GR, Li CY, et al. (2021). Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science 373, eabj0486. 10.1126/science.abj0486. - DOI - PMC - PubMed
    1. Martin TD, Patel RS, Cook DR, Choi MY, Patil A, Liang AC, Li MZ, Haigis KM, and Elledge SJ (2021). The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation. Science 373, 1327–1335. 10.1126/science.abg5784. - DOI - PubMed
    1. Leach DR, Krummel MF, and Allison JP (1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736. 10.1126/science.271.5256.1734. - DOI - PubMed
    1. Dong H, Zhu G, Tamada K, and Chen L (1999). B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5, 1365–1369. 10.1038/70932. - DOI - PubMed
    1. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192, 1027–1034. 10.1084/jem.192.7.1027. - DOI - PMC - PubMed

LinkOut - more resources